Evidence map›Paper›PMID 34465343›Full record

ArticleJournal of experimental & clinical cancer research : CR2021

CIRP promotes the progression of non-small cell lung cancer through activation of Wnt/β-catenin signaling via CTNNB1.

Yi Liao, Jianguo Feng, Weichao Sun, Chao Wu, Jingyao Li, Tao Jing, Yuteng Liang, Yonghui Qian, Wenlan Liu, Haidong Wang

Open access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 47 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. COX-2 in lung cancer: Mechanisms, development, and targeted therapies.Chronic diseases and translational medicine · 2024
    Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Yi Liao *The Central Laboratory, Shenzhen Second People's Hospital/First Affiliated Hospital of Shenzhen University Health Science Center, Shenzhen, Guangdong, 518035, P. R. China.
Jianguo Feng *Department of Anesthesiology, The Affiliated Hospital of Southwest Medical University, Province, Luzhou, 646099, Sichuan, China.
Weichao SunThe Central Laboratory, Shenzhen Second People's Hospital/First Affiliated Hospital of Shenzhen University Health Science Center, Shenzhen, Guangdong, 518035, P. R. China.
Chao WuDepartment of Thoracic Surgery, Southwest Hospital, Army Medical University, Chongqing, 400038, P. R. China.
Jingyao LiThe Central Laboratory, Shenzhen Second People's Hospital/First Affiliated Hospital of Shenzhen University Health Science Center, Shenzhen, Guangdong, 518035, P. R. China.
Tao JingDepartment of Cardiology, Southwest Hospital, Army Medical University, Chongqing, 400038, P. R. China.
Yuteng LiangDepartment of Thoracic Surgery, Shenzhen Second People's Hospital/First Affiliated Hospital of Shenzhen University Health Science Center, Shenzhen, Guangdong, 518035, P. R. China.
Yonghui QianDepartment of Thoracic Surgery, Shenzhen Second People's Hospital/First Affiliated Hospital of Shenzhen University Health Science Center, Shenzhen, Guangdong, 518035, P. R. China.
Wenlan LiuThe Central Laboratory, Shenzhen Second People's Hospital/First Affiliated Hospital of Shenzhen University Health Science Center, Shenzhen, Guangdong, 518035, P. R. China. wlliu@szu.edu.cn.
Haidong WangDepartment of Thoracic Surgery, Southwest Hospital, Army Medical University, Chongqing, 400038, P. R. China. haidongwang1970@163.com.ORCID http://orcid.org/0000-0003-4409-4339
Shenzhen University Health Science Center · CNArmy Medical University · CNAffiliated Hospital of Southwest Medical University · CN

Funding

China Postdoctoral Science Foundation Grant 2019M663106National Natural Sciences Foundation of China 81702921Shenzhen Science and Technology Commission JCYJ20170413104646428
6 · The paper itself

Abstract

backgroundCold-inducible RNA binding protein (CIRP) is a newly discovered proto-oncogene. In this study, we investigated the role of CIRP in the progression of non-small cell lung cancer (NSCLC) using patient tissue samples, cultured cell lines and animal lung cancer models.

methodsTissue arrays, IHC and HE staining, immunoblotting, and qRT-PCR were used to detect the indicated gene expression; plasmid and siRNA transfections as well as viral infection were used to manipulate gene expression; cell proliferation assay, cell cycle analysis, cell migration and invasion analysis, soft agar colony formation assay, tail intravenous injection and subcutaneous inoculation of animal models were performed to study the role of CIRP in NSCLC cells; Gene expression microarray was used to select the underlying pathways; and RNA immunoprecipitation assay, biotin pull-down assay, immunopurification assay, mRNA decay analyses and luciferase reporter assay were performed to elucidate the mechanisms. The log-rank (Mantel-Cox) test, independent sample T-test, nonparametric Mann-Whitney test, Spearman rank test and two-tailed independent sample T-test were used accordingly in our study.

resultsOur data showed that CIRP was highly expressed in NSCLC tissue, and its level was negatively correlated with the prognosis of NSCLC patients. By manipulating CIRP expression in A549, H460, H1299, and H1650 cell lines, we demonstrated that CIRP overexpression promoted the transition of G1/G0 phase to S phase and the formation of an enhanced malignant phenotype of NSCLC, reflected by increased proliferation, enhanced invasion/metastasis and greater tumorigenic capabilities both in vitro and in vivo. Transcriptome sequencing further demonstrated that CIRP acted on the cell cycle, DNA replication and Wnt signaling pathway to exert its pro-oncogenic action. Mechanistically, CIRP directly bound to the 3'- and 5'-UTRs of CTNNB1 mRNA, leading to enhanced stability and translation of CTNNB1 mRNA and promoting IRES-mediated protein synthesis, respectively. Eventually, the increased CTNNB1 protein levels mediated excessive activation of the Wnt/β-catenin signaling pathway and its downstream targets C-myc, COX-2, CCND1, MMP7, VEGFA and CD44.

conclusionOur results support CIRP as a candidate oncogene in NSCLC and a potential target for NSCLC therapy.

Indexed as

Wnt Signaling PathwayAnimalsbeta CateninCarcinoma, Non-Small-Cell LungCell LineCell ProliferationDisease ProgressionFemaleHumansLung NeoplasmsMiceMice, Inbred BALB CPrognosisRNA-Binding ProteinsRNA, Messengerbeta CateninCIRBP protein, humanCTNNB1 protein, humanRNA-Binding ProteinsRNA, MessengerCIRPCTNNB1Non-small cell lung cancerWnt/β-catenin

Identifiers

PMID34465343
PMCPMC8406911
OpenAlexW3154869055

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.